Compare TBBK & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | VCEL |
|---|---|---|
| Founded | 1999 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2005 | 1996 |
| Metric | TBBK | VCEL |
|---|---|---|
| Price | $46.91 | $40.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $76.00 | $59.71 |
| AVG Volume (30 Days) | 414.4K | ★ 519.3K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 60.00 |
| EPS | ★ 2.86 | N/A |
| Revenue | $141,147,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $21.71 |
| Revenue Next Year | $0.56 | $16.86 |
| P/E Ratio | $17.69 | ★ N/A |
| Revenue Growth | ★ 20.85 | 16.45 |
| 52 Week Low | $47.01 | $28.95 |
| 52 Week High | $73.02 | $49.32 |
| Indicator | TBBK | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 46.26 |
| Support Level | N/A | $38.19 |
| Resistance Level | $51.47 | $41.06 |
| Average True Range (ATR) | 1.47 | 1.57 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 9.70 | 16.41 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.